The Diabetes Drug Landscape Is Moving Far Beyond Insulin

For more than a century, insulin has been central to diabetes treatment.

It remains essential, particularly for people living with Type 1 diabetes, and continues to save millions of lives.

But the diabetes treatment landscape is changing rapidly.

GLP-1 therapies. Dual agonists. Triple-hormone treatments. Amylin combinations. Oral metabolic medications. Cell therapies.

These developments are transforming how researchers approach diabetes, obesity, and metabolic health.

At the American Diabetes Association (ADA) 2026 Scientific Sessions, held June 5–8 in New Orleans, researchers presented findings that highlighted just how far diabetes treatment is moving beyond traditional glucose-lowering strategies.

Additionally, research published in leading medical journals has reinforced the scientific significance of several of these developments.

The emerging picture is clear: the next generation of diabetes care will offer more treatment options, more mechanisms of action, and increasingly individualized approaches to managing metabolic health.

GLP-1 therapies opened the door to a new generation of treatments

GLP-1 receptor agonists have already changed how Type 2 diabetes and obesity are treated.

Unlike insulin, which directly replaces or supplements the body's insulin supply, GLP-1 therapies influence several physiological processes, including glucose-dependent insulin secretion, appetite, and gastric emptying.

The development of dual-hormone therapies expanded this approach.

Tirzepatide, for example, activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors.

Now researchers are investigating whether targeting three hormone pathways simultaneously can deliver additional benefits.

One of the most closely watched developments at ADA 2026 was retatrutide, an investigational once-weekly injectable that activates GIP, GLP-1, and glucagon receptors.

Researchers presented Phase 3 findings from the TRANSCEND-T2D-1 and TRIUMPH-1 clinical trials, examining the drug's effects on glucose control, body weight, and obesity-related outcomes.

The TRANSCEND-T2D-1 trial, also published in The Lancet, provided peer-reviewed evidence of improvements in glycemic control and body weight among adults with Type 2 diabetes.

Retatrutide remains investigational, and its long-term place in clinical practice has not yet been established.

Nevertheless, its development represents an important shift in metabolic medicine.

Rather than targeting a single biological pathway, researchers are increasingly exploring how multiple hormonal mechanisms can work together.

 

Diabetes medications are being developed to address more than blood glucose

Another major theme at ADA 2026 was the expanding definition of what diabetes treatments are expected to accomplish.

Historically, diabetes treatment was discussed primarily in terms of reducing blood glucose and achieving target A1C levels.

Today, clinical research increasingly evaluates a broader range of outcomes, including:

• Blood glucose control and time in range

• Weight reduction

• Cardiovascular and kidney health

• Liver health

• Insulin requirements

• Overall metabolic health and quality of life

This broader approach was reflected in research involving dual- and triple-hormone agonists, amylin-based combinations, and other emerging metabolic therapies.

For example, ADA 2026 featured Phase 3 findings from the REIMAGINE clinical program investigating CagriSema, a combination of the amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide.

Amylin is a hormone normally released alongside insulin that contributes to appetite regulation and glucose control.

Combining amylin and GLP-1 pathways represents another strategy for addressing several metabolic processes within one treatment.

These developments suggest that the future of diabetes care will increasingly focus on treating the broader metabolic condition rather than blood glucose in isolation.

 

Even Type 1 diabetes research is moving beyond insulin alone

Some of the most interesting developments being presented today involve Type 1 diabetes.

Insulin remains indispensable for people with Type 1 diabetes. The emerging treatments discussed here are not substitutes for prescribed insulin therapy.

However, researchers are exploring whether medications traditionally associated with Type 2 diabetes and obesity could provide additional benefits for selected people with Type 1 diabetes.

In the Phase 2 results for acmopatide (CT-868), an investigational dual GLP-1/GIP receptor agonist evaluated in adults with Type 1 diabetes who had overweight or obesity, researchers report improvements in glycemic control, along with reductions in body weight and insulin requirements in treatment groups.

These findings are encouraging, but the study was relatively small and short in duration. Larger, longer-term studies are needed to establish safety, efficacy, and the appropriate role of acmopatide in Type 1 diabetes care.

The broader significance is that researchers are beginning to explore new ways of addressing the metabolic challenges associated with Type 1 diabetes, beyond insulin replacement alone.

 

The future of diabetes treatment is not limited to injections

Although injectable medications remain central to diabetes care, not every innovation is moving toward another injection.

One prominent example is orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist.

Results from the ACHIEVE clinical program presented at ADA 2026 examined its effects on blood glucose and weight compared with other treatment options.

Researchers also presented Phase 2 findings for elecoglipron (AZD5004), another investigational oral GLP-1 therapy, reporting improvements in glycemic and weight-related outcomes.

These studies reflect a growing effort to offer patients more flexibility in how metabolic treatment is delivered.

The oral GLP-1 landscape continues to evolve, and the future of diabetes care is unlikely to involve one type of medication replacing every other treatment.

Instead, it may include a much broader selection of options:

Daily and weekly injections.

Oral medications.

Combination therapies.

Automated insulin delivery systems.

And, potentially, therapies designed to restore the body's ability to produce insulin.

 

Could future treatments restore the body's ability to produce insulin?

One of the most ambitious areas of Type 1 diabetes research is focused on restoring insulin production rather than simply replacing insulin through injections or pumps.

Scientists are developing stem-cell-derived islet cell therapies intended to replace the insulin-producing cells destroyed by the autoimmune process underlying Type 1 diabetes.

These approaches could eventually change treatment for some patients.

Clinical research has already demonstrated that transplanted stem-cell-derived islet cells can produce insulin in selected patients, providing important proof of concept.

However, substantial challenges remain.

These include immune rejection, the potential need for immunosuppressive treatment, long-term durability, manufacturing, patient selection, cost, and regulatory requirements.

Cell replacement therapies remain experimental and are not established alternatives to routine insulin therapy.

Still, their development illustrates how broad the field has become.

The future may include better insulin formulations and delivery systems.

It may include medications that work alongside insulin.

And researchers hope that, for some patients, it may eventually include therapies that reduce or eliminate the need for externally administered insulin.

 

More treatment options bring new responsibilities outside the clinic

The scientific progress is exciting.

But there is another aspect of diabetes treatment innovation that deserves greater attention.

As the number and variety of medications expand, so do the practical responsibilities that come with them.

Many diabetes and metabolic therapies are administered by patients themselves.

At home.

At work.

While traveling.

At school.

In cars, handbags, backpacks, hotel rooms, airports, and outdoor environments.

And many injectable medications have specific storage requirements.

Some must be refrigerated before first use. Others may be kept at room temperature for a defined period after opening or dispensing. Certain products require protection from excessive heat, freezing, or light.

 

These requirements are not interchangeable.

The storage conditions appropriate for one injectable medication should never automatically be assumed to apply to another.

As the diabetes treatment landscape becomes more diverse, understanding how each medication should be stored becomes an important part of understanding how it should be used.

 

The last mile of medication care matters

A medication may be developed using advanced biotechnology, tested through rigorous clinical trials, and prescribed with precision.

But eventually, it leaves the controlled environment of the pharmacy.

The patient takes over.

And that final stage of the medication journey matters.

The U.S. Food and Drug Administration warns that exposure to extreme temperatures can reduce insulin effectiveness. Its guidance also emphasizes protecting insulin from freezing, direct heat, and sunlight.

More broadly, temperature-sensitive medications must be handled according to their individual manufacturer instructions.

The implications are important.

A treatment's scientific sophistication does not eliminate the need for proper storage during everyday use.

As diabetes care becomes increasingly personalized, medication protection must remain part of the broader conversation about treatment quality and patient confidence.

 

Innovation in diabetes care should extend beyond the medication itself

At TempraMed, we believe that advances in medication development should be accompanied by innovation in how temperature-sensitive medications are protected in everyday life.

VIVI solutions use patented passive thermal protection technology designed for compatible temperature-sensitive medications, without relying on ice, batteries, or continuous user intervention.

As the range of injectable treatments expands, practical solutions that help patients follow appropriate medication storage requirements will become increasingly relevant.

The developments highlighted at ADA 2026 demonstrate how rapidly diabetes treatment is evolving.

More mechanisms of action.

More personalized therapies.

More choices for patients.

And new possibilities for managing a condition that affects hundreds of millions of people worldwide.

But scientific progress does not end when a medication receives regulatory approval or leaves the pharmacy.

It continues through every stage of the patient's treatment journey.

Because developing better medicine is only part of the challenge.

Keeping that medicine protected until the moment it is needed matters too.

At TempraMed, we believe that advances in medication development should be accompanied by innovation in how temperature-sensitive medications are protected, tracked, and managed in everyday life.

As the range of injectable treatments expands, so does the need for practical solutions that not only help protect medications but also support patients in managing increasingly complex treatment schedules, tracking injections, and maintaining consistent medication routines.

The developments highlighted here demonstrate how rapidly diabetes treatment is evolving.

More mechanisms of action.

More personalized therapies.

More choices for patients.

More complex treatment routines that require better tracking, greater visibility, and ongoing support.

And new possibilities for managing a condition that affects hundreds of millions of people worldwide.

But scientific progress does not end when a medication receives regulatory approval or leaves the pharmacy.

It continues through every stage of the patient's treatment journey.

Because developing better medicine is only part of the challenge. Ensuring every dose is protected, every injection tracked, and that patients have the tools to stay on top of their treatment is equally important.

Scientific references

1. American Diabetes Association. 2026 Scientific Sessions. New Orleans, June 5–8, 2026.

2. American Diabetes Association. Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity. June 6, 2026.

3. The Lancet. Efficacy and safety of retatrutide in people with Type 2 diabetes: TRANSCEND-T2D-1. 2026.

4. American Diabetes Association. First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits. June 5, 2026.

5. American Diabetes Association. ACHIEVE Trials Demonstrate Comparative Benefits of Novel Small-Molecule Oral GLP-1 RA. June 8, 2026.

6. American Diabetes Association. Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results. June 8, 2026.

7. New England Journal of Medicine. Research on stem-cell-derived islet therapies for Type 1 diabetes. 2025.

8. U.S. Food and Drug Administration. Information Regarding Insulin Storage and Switching Between Products in an Emergency.